Immunovant Swaps Out Lead Assets

 
• By Jessica Merrill

The Roivant-owned company plans to initiate a broad clinical trial program for IMVT-1402 in multiple indications, prioritizing it over batoclimab, which remains in Phase III development. 

switching directions
Immunovant is switching its lead asset • Source: Shutterstock (Stockimo/Shutterstock)

More from Strategy

More from Business